EGFR and neoplasm: The first is that SpTR can reduce the residual tumour burdens, which are required to generate an effective immune response in immunotherapies such as CAR-T therapies (37), HSPPC-96 vaccination (27) and rindopepimut (a peptide vaccine against EGFR-vIII-expressing GBMs).